Social Media Ideas for Antibody-Drug Conjugates

DualityBio Enters a Global Collaboration and License Agreement with Genentech to Develop Next-Generation ADCs Built on D...

Collaboration leverages DualityBio's proprietary DUPAC payload platform and early global clinical development capabilities, with Genentech assuming further clinical development and...

How AOCs are advancing targeted therapeutics

The concept of targeted therapeutics is often traced back to German Nobel laureate Paul Ehrlich’s “magic bullet” in 1907, which envisioned a single entity that could both recognize...

The Next Wave of ADC Innovation: The Science Behind Dual-Payload Bioconjugates

In this GEN webinar, our expert speaker, Cindy Cheng, PhD, will explore how mechanism-driven payload pairing counters specific resistance pathways by combining orthogonal or comple...

ADCs, mAbs, CAR Ts: One Bioluminescent Platform Measures Them All

The HiBiT Target Cell Killing (TCK) platform, with off-the-shelf, mix-and-match components, measures four killing mechanisms for broad immunotherapy modality assessment. The post A...

ESMO 2026 Preview | Mabwell to Present Clinical Results for Nectin-4-Targeting ADC 9MW2821 in ADC-Pretreated Triple-Nega...

SHANGHAI, Oct. 18, 2026 /PRNewswire/ -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, will present Phase II...

B7-H3 ADCs: A new contender in small cell lung cancer and beyond 

Delve into the field of B7-H3 ADCs, a new contender in SCLC cancer as Hansoh Pharma and Medilink bring momentum with positive results. The post B7-H3 ADCs: A new contender in small...

Skin Side Effects of Breast Cancer Drug Sacituzumab Govitecan Are Mostly Mild, Global Study Finds

Sacituzumab govitecan has become one of the most consequential weapons in modern oncology, a so-called antibody–drug conjugate that delivers a potent chemotherapy payload directly...

Roche, Hansoh Launch Up-to-$15B+ Cancer ADC Collaboration

The companies' strategic collaboration will consist of two preclinical Hansoh ADC programs and “multiple” ADC programs based on Roche-identified targets, to be developed through Ha...

ZoeNCure Therapeutics Secures License for Novel Antibody Platform from Styx Biotechnologies to Advance Next-Generation A...

Strategic licensing agreement enables ZoeNCure to build a high-potency, ADC pipeline targeting severe gastrointestinal and liver cancers in India. 

Dual-acting drug from AbbVie, Genmab scores in frontline lymphoma trial

The better-than-expected results could make Epkinly the new “undisputed” treatment standard in newly diagnosed DLBCL, according to one analyst.

Aptevo Advances Next-Generation Trispecific Candidate Toward Clinical Development

Company Making Critical Progress in Scalable Manufacturing and Preparing the Lead Trispecific Candidate for Future Human TestingTrispecifics Combine Three Complementary Cancer-Figh...

CAR-T Made easy

Chimeric antigen receptor (CAR) therapy is away you harness the specificity potential of antibodies and the killing potential of T cells. You make T cells to express bits of an ant...

GSK wagers up to $1.3B on a different kind of cancer drug

With its latest foray into China, GSK acquired rights from Hutchmed to an “antibody-targeted therapy conjugate” impacting two well-known cancer drivers, EGFR and KRAS.

<![CDATA[Regeneron and Sanofi Expand Antibody Alliance with Four New Drugs]]>

GSK Pays $110M for Phase 1-Ready Hutchmed Asset in a New Class of Cancer Drugs

GSK gained rights to a Hutchmed antibody-targeted therapy conjugate, or ATTC. This new type of targeted therapy blocks two cancer-driving proteins and will initially be developed f...

Eli Lilly releases promising early-stage data on ADC for ovarian cancer

Hype vs. reality: What pharma’s hottest R&D bets have actually proved

New types of bispecifics, antibody-drug conjugates and cell therapies haven’t yet proven themselves in the clinic. Pharmaceutical companies are betting billions anyway.

ADC Developmentfrom Concept to Clinic

This eBook brings insight on integrated end-to-end solutions for precision engineered therapeutics. The post ADC Developmentfrom Concept to Clinic appeared first on GEN - Genetic E...

Extractables in single-use systems used in ADC manufacturing

Explore extractables data supporting single-use systems in ADC manufacturing.

Ginkgo Datapoints, Apheris Announce Founding Members of Antibody Developability Consortium

The consortium aims to address antibody development bottlenecks by creating standardized datasets and AI models that support earlier risk detection and more informed candidate sele...

<![CDATA[M&A Roundup: DualityBio & Genentech Enter Partnership to Develop Next Generation ADC’s, Teva Bids to...

AstraZeneca Places a $2B Bet on a Summit Therapeutics Cancer Drug

AstraZeneca’s equity investment in Summit Therapeutics comes with plans for clinical trial collaborations. The deal brings AstraZeneca into a growing group of pharmaceutical compan...

Bicistornic Vectors + piggyBac = Improved Antibody Cell Line Production

To produce stable cell lines for monoclonal antibody production, manufacturers typically use the piggyBac transposon system. For larger, multi-specific antibodies that have payload...

ZoeNCure Therapeutics Secures INR 20 Crore Seed Investment to Accelerate Next-Generation Antibody Drug Conjugate (ADC) P...

Follow-on investment led by the HNI (High-Net-Worth Individual) Tyagi Family bringing total capital raised to date to INR 22.5 Crore, underscoring strong investor confidence in Zoe...